First in class
-
- We question the claim "First in class" as it is unclear, and unsubstantiated. Please refer us to the exact location of support for this claim. We note the MOA section specifies "First in class recombinant human IgG4 monoclonal antibody". We could consider this statement, however please disclaim with "Clinical significance has not been established" and please position as a nabisco. The claim should not appear as a heading that spans the entire top of the page. ((2.1, s3.1, 2.6.2., s3.1.4)